A health economic model to assess the cost-effectiveness of PEG IFN ?-2a and ribavirin in patients with mild chronic hepatitis C

2007 ◽  
Vol 14 (8) ◽  
pp. 523-536 ◽  
Author(s):  
S. Gerkens ◽  
M. Nechelput ◽  
L. Annemans ◽  
B. Peraux ◽  
M. Mouchart ◽  
...  
Keyword(s):  
Health Economic ◽  
Chronic Hepatitis ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Economic Model ◽  
Health Economic Model ◽  
The Cost

scholarly journals A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States

2018 ◽  
Vol 21 (9) ◽  
pp. 835-844 ◽  
Author(s):  
Mark Nuijten ◽  
Agnieszka Marczewska ◽  
Krysmaru Araujo Torres ◽  
Bahareh Rasouli ◽  
Moreno Perugini
Keyword(s):  
United States ◽  
Health Economic ◽  
Cost Effectiveness ◽  
Economic Model ◽  
The United States ◽  
Health Economic Model ◽  
Treatment Of Obesity ◽  
The Cost

scholarly journals Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients

2013 ◽  
Vol 13 (6) ◽  
Author(s):  
Jakovljevic B. Mihajlo ◽  
Miјailovic D. Zeljko ◽  
Popovska Jovicic D. Biljana ◽  
Canovic S. Predrag ◽  
Gajovic M. Olgica ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Viral Genotype ◽  
Costs Of Care ◽  
The Cost ◽  
Chronic Hepatitis C Patients
Sign in / Sign up

Export Citation Format

Share Document